Compare Repligen Corporation Common Stock (RGEN) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sunrun Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Sunrun Inc trades at $7.27 (market cap $1.88B). The key difference: Repligen Corporation Common Stock is far larger — about 5.9× Sunrun Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sunrun Inc for 16 Days on average.
| RGEN | RUN | |
|---|---|---|
Market Cap | $11.14B | $1.88B |
Volume | 1,259,263 | 7,327,146 |
Sector | Health | Energy |
52-Week High | $194.57 | $21.41 |
52-Week Low | $102.87 | $7.30 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $11.02B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Sunrun (RUN) trades at $7.79, up 2.64% on the day, but remains in a bearish technical trend with strong selling pressure in moving averages. The stock shows attractive valuation metrics with P/E of 5.3 and P/B of 0.54, while consistently beating earnings expectations in recent quarters. Recent developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.
Despite positive analyst sentiment (62% buy ratings) and a $15.40 consensus price target representing 98% upside, RUN faces significant headwinds including negative operating cash flow, high debt levels (70.76% debt-to-asset ratio), and solar industry pressure from elevated borrowing costs. The stock trades near its analyst low target of $7.00, suggesting limited downside but requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
